[19] Importantly, do not stop insulin or rapidly reduce insulin doses when starting a GLP-1 medication, as this can increase the risk of diabetic ketoacidosis (DKA)
You need a purposeful one
For obesity, adults eligible for a prescription must have a body mass index of at least 30 or a BMI between 27 and 30, along with at least one weight-related health condition, such as type 2 diabetes, high cholesterol, or high blood pressure
This leads to: Reduced hunger , making portion control easier
Since exenatide is the only GLP-1 receptor agonist covered by insurance payment in Turkey, we had to perform desensitization in these two patients who were proved to be allergic to exenatide
Consider alternatives to semaglutide for treating obesity until supply stabilizes